Interim data from IGC Pharma’s Phase 2 trial reveals IGC-AD1, a novel drug targeting neuro-inflammation and CB1 receptor dysfunction, demonstrates significant cognitive improvement in Alzheimer’s patients alongside previously reported agitation reduction. This offers potential for a new treatment addressing both symptoms and underlying disease progression.